The OncoScan CNV Assay is a whole-genome copy number microarray-based assay that enables the detection of relevant copy number variations (CNVs) such as copy number gain and loss, loss of heterozygosity (LOH), copy neutral loss of heterozygosity (cnLOH), ploidy, allele specific changes, break point determination, mosaicism, clonal heterogeneity, and chromothripsis. 

Key features of the OncoScan CNV Assay include:

• Whole-genome copy number analysis—detect structural variants such as deletions, duplications, LOH, cnLOH, break point determination, ploidy, mosaicism and unbalanced translocations that are not well characterized by short read sequencing or targeted sequencing
• Comprehensive coverage—whole-genome analysis of genes with established significance and importance in cancer and tumor progression as well as those with emerging evidence, helping to ‘future-proof’ the technology investment and minimize revalidation burden
• Complete flexibility—detect chromosomal arm aberrations, focal changes, LOH, and cnLOH in a single assay, helping reduce costs and processing times
• Robust performance—obtain standardized results from lot to lot and operator to operator
• Low sample input and fast results—get results in 72 hours from only 80 ng of FFPE-derived DNA
• Rapid analysis—free software provides intuitive data visualizations for hundreds of samples in minutes
• High-resolution copy number detection in priority cancer genes—accurate identification of very small (50–125 kb) to large (Mb) copy number variations

The assay has the same copy number coverage as the OncoScan CNV Plus Assay but does not include somatic mutation coverage. It provides the reagents for sample preparation from formalin-fixed paraffin-embedded (FFPE) tumor samples and microarray hybridization and staining. 

Data analysis is free of charge and easy using one of the three available softwares: Chromosome Analysis Suite (ChAS), Somatic Mutation Viewer 1.1, and Nexus Express software.

DOWNLOADABLE BROCHURE:
OncoScan CNV and CNV Plus Assays